Identifying Treatment Regimens for Patients with Multiple Myeloma
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, advises on the best way to choose treatment regimens for patients with multiple myeloma. Since 9 different drugs have been approved after many phase III trials, a community physician may be overwhelmed by this surplus of options, Chari says.
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, advises on the best way to choose treatment regimens for patients with multiple myeloma. Since 9 different drugs have been approved after many phase III trials, a community physician may be overwhelmed by this surplus of options, Chari says.
It is difficult to compare results across trials, Chari says. Each trial will have a different outcome, depending on patient factors, such as age, performance status, and comorbidities, disease factors, including burden of disease, molecular biology of the disease, or treatment issues like toxicity of the drug.
